23 Feb BioCentriq
Haro Hartounian, Ph.D., CEO
Oct. 11 | 9:30am | Oxford Biomedica Ballroom
BioCentriq is a premier cell and gene therapy development and manufacturing center located in New Jersey. The company operates multiple GMP and process development facilities and has in-house analytical method development capabilities. BioCentriq currently supports Phase I-III clinical trials with commercial manufacturing capabilities planned in the near future. Through its Hybrid Team Model, BioCentriq offers a collaborative environment in which clients are welcomed and encouraged to participate in development and manufacturing activities under the guidance of experienced staff. BioCentriq’s expertise spans across autologous and allogeneic cell therapies such as T cells, CAR T, MSC/iPSC, NK cells, dendritic cells, HEK 293(T), Sf9, and in viral vectors such as AAV, adenovirus, retrovirus, and lentiviral vectors with a maximum production capacity of 200L.